Integrated Diagnostics Holdings PLC Results of EGM and Subdivision of Share Capital (7209J)
December 23 2020 - 8:35AM
UK Regulatory
TIDMIDHC
RNS Number : 7209J
Integrated Diagnostics Holdings PLC
23 December 2020
For immediate release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF
SUCH JURISDICTION.
Results of Extraordinary General Meeting and Subdivision of
Share Capital
Integrated Diagnostics Holdings ("IDH" or the "Company"), a
leading consumer healthcare company with operations in Egypt,
Jordan, Sudan, and Nigeria, announces that, further to its circular
posted on 4 December 2020 (the "Circular"), at the Extraordinary
General Meeting (the "EGM") of the Company held earlier today at
the headquarters of IDH Integrated Diagnostics Holdings, Building
B216-F7, Smart Village, Giza, Egypt, all resolutions contained in
the notice of the meeting appended to the Circular were duly
passed.
Further information on the resolutions and the voting report
will be available on the Company's website at
https://investors.idhcorp.com/
Under Listing Rule 9.6, a copy of the resolutions will be
submitted to the National Storage Mechanism, and available to view
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
The Company will now progress the Subdivision (as defined in the
Circular).
Subdivision
Following the passing of the relevant resolutions at the EGM,
with effect from tomorrow, the Company's existing issued ordinary
share capital of 150,000,000 ordinary shares of US$1.00 each (the
"Existing Ordinary Shares") will be sub-divided on the basis of one
Existing Ordinary Shares into four new ordinary shares of US$0.25
each (the "New Ordinary Shares"). Details of the Subdivision and
the effect on shareholders were set out in the Circular.
The ISIN of the New Ordinary Shares is JE00BLKGSR75 and the
SEDOL is BLKGSR7. The New Ordinary Shares are expected to be
admitted to trading on the Main Market of the London Stock Exchange
at 8.00 am (or as soon as practicable thereafter) on 24 December
2020.
The proportion of the Company's issued ordinary share capital
held by each shareholder immediately before and after the
Subdivision will remain unchanged.
Shareholders who held their Existing Ordinary Shares in CREST
prior to the Subdivision will have the New Ordinary Shares credited
to their CREST accounts as soon as practicable today. Shareholders
who held their Existing Ordinary Shares in certificated form will
have new share certificates evidencing the New Ordinary Shares to
which they are entitled dispatched to them by first-class post by
on or around 4 January 2021.
Total Voting Rights
With effect from tomorrow, the Company's issued ordinary share
capital will comprise 600,000,000 New Ordinary Shares, with one
voting right each. The Company does not hold any shares in
treasury. This figure of 600,000,000 may be used by shareholders in
the Company as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
under the FCA's Disclosure Guidance and Transparency Rules.
About Integrated Diagnostics Holdings (IDH)
IDH is a leading consumer healthcare company in the Middle East
and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The
Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar
in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar
Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record
for quality and safety has earned the Company a trusted reputation,
as well as internationally recognised accreditations for its
portfolio of over 1,400 diagnostics tests. From its base of 471
branches as of 30 September 2020, IDH will continue to add
laboratories through a Hub, Spoke and Spike business model that
provides a scalable platform for efficient expansion. Beyond
organic growth, the Group's expansion plans include acquisitions in
new Middle Eastern and African markets where its model is
well-suited to capitalise on similar healthcare and consumer trends
and capture a significant share of fragmented markets. IDH has been
a Jersey-registered entity with a Standard Listing on the Main
Market of the London Stock Exchange (ticker: IDHC) since May 2015.
Learn more at idhcorp.com .
Contact
Nancy Fahmy
Investor Relations Director
T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 |
nancy.fahmy@idhcorp.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMFZMZZFFDGGZM
(END) Dow Jones Newswires
December 23, 2020 08:35 ET (13:35 GMT)
Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart
From Apr 2024 to May 2024
Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart
From May 2023 to May 2024